

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

## Eticovo (etanercept-ykro)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Eticovo (etanercept-ykro) 25 mg/0.5 mL prefilled syringe*	8 syringes per 28 days
Eticovo (etanercept-ykro) 50 mg/mL prefilled syringe*	4 syringes per 28 days

\*Initiation of therapy for adult Plaque Psoriasis (Ps): May approve up to 2 (two) additional 25 mg vials (25 mg/mL) or syringes [(25 mg/0.5 mL (0.51 mL)] **OR** 1 (one) additional 50 mg syringe [50 mg/mL (0.98 mL)], pen (50 mg/0.5 mL), or autoinjector [50 mg/mL (0.98 mL)] per week in the first 3 months (84 days) of treatment.

### APPROVAL CRITERIA

Requests for Eticovo (etanercept-ykro) may be approved for the following:

- I. Rheumatoid arthritis (RA) when each of the following criteria are met:
  - A. Individual is 18 years of age or older with moderate to severe RA; **AND**
  - B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [nonbiologic disease modifying anti-rheumatic agents (DMARDs) such as methotrexate, sulfasalazine, leflunomide, or hydroxychloroquine)] (ACR 2015); **AND**
  - C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred agents [Current preferred agents include – Enbrel (etanercept), Humira (adalimumab)] unless the following criteria are met:
    1. Individual has been receiving and is maintained on a stable dose of Eticovo (etanercept-ykro);

### **OR**

- II. Ankylosing spondylitis (AS) when each of the following criteria are met:
  - A. Individual is 18 years of age or older with moderate to severe AS; **AND**
  - B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [such as NSAIDs or nonbiologic disease

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

modifying anti-rheumatic drugs (DMARDs) (such as sulfasalazine)] (ACR 2019);

**AND**

- C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Enbrel (etanercept), Humira (adalimumab)] unless the following criteria are met:
1. Individual has been receiving and is maintained on a stable dose of Eticovo (etanercept-ykro);

**OR**

- III. Polyarticular juvenile idiopathic arthritis (PJIA) when each of the following criteria are met:
- A. Individual is 2 years of age or older with moderate to severe PJIA; **AND**
  - B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [nonbiologic disease modifying anti-rheumatic agents (DMARDs) (such as methotrexate)] (ACR 2019);

**AND**

- C. Individual has had a trial (medication samples/coupons/discount cards are excluded from as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Enbrel (etanercept), Humira (adalimumab)] unless the following criteria are met:
1. Individual has been receiving and is maintained on a stable dose of Eticovo (etanercept-ykro);

**OR**

- IV. Psoriatic arthritis (PsA) when each of the following criteria are met:
- A. Individual is 18 years of age or older with moderate to severe PsA; **AND**
  - B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to conventional therapy [nonbiologic disease modifying anti-rheumatic drugs (DMARDs) (such as methotrexate, sulfasalazine, or leflunomide)] (AAD 2011);

**AND**

- C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Enbrel (etanercept), Humira (adalimumab)] unless the following criteria are met:
1. Individual has been receiving and is maintained on a stable dose of Eticovo (etanercept-ykro);

**OR**

- V. Plaque psoriasis (Ps) (Psoriasis vulgaris) when each of the following criteria are met:
- A. Individual is 4 years of age or older with chronic moderate to severe (that is, extensive or disabling) plaque Ps (psoriasis vulgaris) with either of the following (AAD 2019):
    1. Plaque Ps (psoriasis vulgaris) involving greater than three percent (3%) body

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

surface area (BSA); **OR**

2. Plaque Ps (psoriasis vulgaris) involving less than or equal to three percent (3%) of BSA involving sensitive areas or areas that significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia); **AND**

B. Individual has had an inadequate response to, is intolerant of, or has a contraindication to phototherapy or other systemic therapies (such as acitretin, cyclosporine, or methotrexate);

**AND**

C. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to TWO (2) preferred biologic agents [Current preferred biologics include – Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab)] unless the following criteria are met:

1. Individual has been receiving and is maintained on a stable dose of Eticovo (etanercept-ykro).

Requests for Eticovo (etanercept-ykro) may **not** be approved for the following:

- I. All other indications not included above; **OR**
- II. In combination with other TNF antagonists, apremilast, JAK inhibitors, other biologic drugs (such as, abatacept, anakinra, vedolizumab), or cyclophosphamides; **OR**
- III. Tuberculosis, other active serious infections, or a history of recurrent infections; **OR**
- IV. Individual has not had a tuberculin skin test (TST), or a Centers for Disease Control (CDC-) and Prevention -recommended equivalent to evaluate for latent tuberculosis prior to initiating etanercept-szszs.

**Note:**

TNFi have black box warnings for serious infections and malignancy. Individuals treated with TNFi are at increased risk for developing serious infections that may lead to hospitalization or death. Most individuals who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. TNFi should be discontinued if an individual develops a serious infection or sepsis. Individuals should be tested for latent tuberculosis (TB) before TNFi use and during therapy. Treatment for latent TB should be initiated prior to TNFi use. Risks and benefits of TNFi should be carefully considered prior to initiation of therapy in individuals with chronic or recurrent infection. Lymphoma and other malignancies have been reported in children and adolescents treated with TNFi. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in individuals treated with TNFi. Almost all cases had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNFi at or prior to diagnosis. It is uncertain whether HSTCL is related to the use of a TNFi or a TNFi in combination with these other immunosuppressants.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. Brunner HI, Ruperto N, Tzaribachev N, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. *Ann Rheum Dis*. 2018; 77(1):21-29.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 14, 2018.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
6. NCCN Drugs & Biologics Compendium (NCCN Compendium®) 2016 National Comprehensive Cancer Network, Inc. Available at: [NCCN.org](http://NCCN.org). Updated periodically. Accessed on: September 14, 2018.
7. Singh JA, Saag KG, Bridges SL et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheum*. 2016;68:1-26.
8. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019; 80: 1029-72.
9. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheum*. 2019; 71(1): 5-32.
10. Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. *Arthritis Rheum*. 2013; 65(10):2499-2512.
11. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Entesitis. *Arthritis Rheum*. 2019; 71(6):846-863.
12. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care & Research*. 2011; 63(4):465-482.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.